Suggested remit: To appraise the clinical and cost effectiveness of bimekizumab within its marketing authorisation for treating moderate to severe hidradenitis suppurativa
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
| Process |
STA Standard
|
| ID number |
6134
|
Provisional Schedule
| Committee meeting: 1 |
11 September 2024 |
| Expected publication |
20 November 2024 |
Project Team
| Project lead |
Thomas Feist |
Email enquiries
| External Assessment Group |
Centre for Reviews and Dissemination and Centre for Health Economics, University of York |
Stakeholders
| Companies sponsors |
UCB Pharma |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Professional groups |
British Association of Dermatologists |
| |
Royal College of Physicians |
| Comparator companies |
Novartis |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
Board of Community Health Councils in Wales |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
National Association of Primary Care |
| |
National Pharmacy Association |
| |
NHS Confederation |
| |
Scottish Medicines Consortium |
| |
Welsh Health Specialised Services |
| |
Committee |
|
Date
|
Update
|
|
12 February 2024
|
Invitation to participate |
|
19 October 2023
|
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-February 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
|
24 March 2023 - 25 April 2023
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
|
24 March 2023
|
In progress. Scoping commenced |
|
16 May 2022
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual